Evaluating the Therapeutic Application of Neuromodulation in the Human Swallowing System.
Ivy Cheng, Ayodele Sasegbon, Shaheen Hamdy
PMID 36239821WHAT IT FOUND
Neuromodulation techniques like rTMS, tDCS, and PES show mixed results for neurogenic dysphagia.
While PES has regulatory approval in Europe and aids extubation in tracheostomized patients, most other applications remain experimental, lack standardized protocols, and are not approved for dysphagia by the FDA.
Key findings
01Pharyngeal electrical stimulation (PES) is CE-marked for dysphagia treatment in Europe but lacks FDA approval in the United States, whereas rTMS and tDCS are approved for depression but not dysphagia.
02In tracheostomized patients with neurogenic dysphagia, PES significantly increases extubation rates compared to sham stimulation.
03Clinical guidelines recommend that neuromodulation for post-stroke dysphagia should primarily be conducted within clinical trials or registries due to limited data and protocol heterogeneity.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Heterogeneity in stimulation protocols (frequency, intensity, hemisphere, duration) makes direct comparison across studies difficult. Many studies have small sample sizes and varying patient characteristics (acute vs. chronic stroke, different etiologies). There is a lack of consensus on optimal treatment parameters, and long-term effects beyond three months are not well understood. Individual variability in responsiveness to neuromodulation, influenced by genetics and lesion location, is poorly characterized.
Declared interests
The text does not explicitly list author conflicts of interest or funding sources for this review article itself, though it discusses regulatory and cost barriers.
The easy way to misread this
Do not assume that neuromodulation techniques are ready for routine clinical practice. Despite promising mechanisms and some positive trial results, guidelines recommend their use primarily within clinical trials or registries due to inconsistent efficacy, lack of standardized protocols, and limited regulatory approval for dysphagia in many jurisdictions.